علاج كوفيد-19 الخفيف إلى المتوسط في المرضى الخارجيين ذوي الخطر المرتفع للتطور

References

DOI: 10.1093/cid/ciac724

• In ambulatory patients with mild-to-moderate COVID-19 at high risk for progression to severe disease, the IDSA guideline panel suggests nirmatrelvir/ritonavir initiated within 5 days of symptom onset rather than no nirmatrelvir/ritonavir.
• Mild-to-moderate illness is defined as patient with SpO2 >94% not requiring supplemental oxygen.
• Among patients (ambulatory or hospitalized) with mild-to-moderate COVID-19 at high risk for progression to severe disease, the IDSA guideline panel suggests remdesivir initiated within 7 days of symptom onset rather than no remdesivir.
• Among ambulatory patients with mild-to-moderate COVID-19 at high risk for progression to severe disease, the IDSA guideline panel suggests treatment with anti–SARS-CoV-2 monoclonal antibodies with activity against the predominant regional variants within 7 days of symptom onset rather than no anti–SARS-CoV-2 monoclonal antibodies.